On December 17, the FDA approved amivantamab and hyaluronidase-lpuj for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab.

For more information, read the FDA announcement and the Janssen Biotech press release.

Posted on 12/18/2025